Opportunity ID: 362196
This opportunity is no longer listed as open or forecasted.
General Information
| Funding Opportunity Number | HT942526ALSRPTDA |
| Funding Opportunity Title | DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award |
| Agency | Jamie Shortall Grant Officer |
| Document Type | synopsis |
| Version | 1 |
| Opportunity Category | Discretionary |
| Opportunity Category Explanation | Not specified |
| Funding Instrument Type | Grant |
| Category of Funding Activity | Science and Technology and other Research and Development |
| Category Explanation | Not specified |
| Expected Number of Awards | 6 |
| Cost Sharing or Matching Requirement | No |
| Posted Date | May 04, 2026 12:00:00 AM EDT |
| Last Updated Date | May 04, 2026 09:46:42 AM EDT |
| Original Closing Date | Sep 30, 2026 12:00:00 AM EDT |
| Original Closing Date Notes | Not specified |
| Current Closing Date | Sep 30, 2026 12:00:00 AM EDT |
| Current Closing Date Notes | Not specified |
| Estimated Synopsis Date | Not specified |
| Estimated Application Due Date | Not specified |
| Estimated Award Date | Not specified |
| Estimated Project Start Date | Not specified |
| Archive Date | Oct 30, 2026 12:00:00 AM EDT |
| Estimated Total Program Funding | 12,000,000 |
| Award Ceiling | none |
| Award Floor | none |
Assistance Listings
- 12.420 — Military Medical Research and Development
Eligibility
| Eligible Applicants | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Description
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.
Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.
Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.
Additional Information
| Contact | Jamie Shortall Grant Officer |
| Contact Information | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| help@eBRAP.org | |
| Email Description | eBRAP Help Desk |
| Phone | 301-619-2393 |
Additional information
Version History
| Id | 362196 |
| Revision | 0 |
| Opportunity number | HT942526ALSRPTDA |
| Opportunity title | DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award |
| Owning agency code | DOD-AMRAA |
| Opportunity category / Category | D |
| Opportunity category / Description | Discretionary |
| Synopsis / Opportunity id | 362196 |
| Synopsis / Version | 1 |
| Synopsis / Agency code | DOD-AMRAA |
| Synopsis / Agency name | Jamie Shortall Grant Officer |
| Synopsis / Agency phone | 301-619-2393 |
| Synopsis / Agency address desc | eBRAP Help Desk |
| Synopsis / Agency details / Code | AMRAA |
| Synopsis / Agency details / Seed | DOD-AMRAA |
| Synopsis / Agency details / Agency name | Defense Health Agency Contracting Activity – DHACA |
| Synopsis / Agency details / Agency code | DOD-AMRAA |
| Synopsis / Agency details / Top agency code | DOD |
| Synopsis / Top agency details / Code | DOD |
| Synopsis / Top agency details / Seed | DOD |
| Synopsis / Top agency details / Agency name | Department of Defense |
| Synopsis / Top agency details / Agency code | DOD |
| Synopsis / Top agency details / Top agency code | DOD |
| Synopsis / Agency contact phone | 301-619-2393 |
| Synopsis / Agency contact name | Jamie Shortall Grant Officer |
| Synopsis / Agency contact desc | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Synopsis / Agency contact email | help@eBRAP.org |
| Synopsis / Agency contact email desc | eBRAP Help Desk |
| Synopsis / Synopsis desc | Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism. |
| Synopsis / Response date | Sep 30, 2026 12:00:00 AM EDT |
| Synopsis / Response date desc | Not specified |
| Synopsis / Posting date | May 04, 2026 12:00:00 AM EDT |
| Synopsis / Archive date | Oct 30, 2026 12:00:00 AM EDT |
| Synopsis / Cost sharing | No |
| Synopsis / Number of awards | 6 |
| Synopsis / Estimated funding | 12000000 |
| Synopsis / Estimated funding formatted | 12,000,000 |
| Synopsis / Award ceiling | none |
| Synopsis / Award floor | none |
| Synopsis / Applicant eligibility desc | Not specified |
| Synopsis / Create time stamp | May 06, 2026 08:13:10 AM EDT |
| Synopsis / Created date | May 04, 2026 09:46:42 AM EDT |
| Synopsis / Last updated date | May 04, 2026 09:46:42 AM EDT |
| Synopsis / Applicant types 1 / Id | 99 |
| Synopsis / Applicant types 1 / Description | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
| Synopsis / Funding instruments 1 / Id | G |
| Synopsis / Funding instruments 1 / Description | Grant |
| Synopsis / Funding activity categories 1 / Id | ST |
| Synopsis / Funding activity categories 1 / Description | Science and Technology and other Research and Development |
| Synopsis / Response date str | 2026-09-30-00-00-00 |
| Synopsis / Posting date str | 2026-05-04-00-00-00 |
| Synopsis / Archive date str | 2026-10-30-00-00-00 |
| Synopsis / Create time stamp str | 2026-05-06-08-13-10 |
| Agency details / Code | AMRAA |
| Agency details / Seed | DOD-AMRAA |
| Agency details / Agency name | Defense Health Agency Contracting Activity – DHACA |
| Agency details / Agency code | DOD-AMRAA |
| Agency details / Top agency code | DOD |
| Top agency details / Code | DOD |
| Top agency details / Seed | DOD |
| Top agency details / Agency name | Department of Defense |
| Top agency details / Agency code | DOD |
| Top agency details / Top agency code | DOD |
| Synopsis attachment folders 1 / Id | 79533 |
| Synopsis attachment folders 1 / Opportunity id | 362196 |
| Synopsis attachment folders 1 / Folder type | Full Announcement |
| Synopsis attachment folders 1 / Folder name | FY26 ALSRP TDA |
| Synopsis attachment folders 1 / Zip lob size | 583066 |
| Synopsis attachment folders 1 / Created date | May 04, 2026 09:46:53 AM EDT |
| Synopsis attachment folders 1 / Last updated date | May 06, 2026 08:13:10 AM EDT |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Id | 351707 |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Opportunity id | 362196 |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Mime type | application/pdf |
| Synopsis attachment folders 1 / Synopsis attachments 1 / File name | HT942526ALSRPTDA_GG.pdf |
| Synopsis attachment folders 1 / Synopsis attachments 1 / File description | FY26 ALSRP TDA Program Announcement |
| Synopsis attachment folders 1 / Synopsis attachments 1 / File lob size | 730573 |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Created date | May 04, 2026 09:47:10 AM EDT |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Last updated date | May 06, 2026 08:13:10 AM EDT |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Synopsis att folder id | 79533 |
| Synopsis document urls | Not specified |
| Syn att change comments | Not specified |
| Cfdas 1 / Id | 433081 |
| Cfdas 1 / Opportunity id | 362196 |
| Cfdas 1 / Cfda number | 12.420 |
| Cfdas 1 / Program title | Military Medical Research and Development |
| Opportunity pkgs | Not specified |
| Closed opportunity pkgs 1 / Id | 292625 |
| Closed opportunity pkgs 1 / Topportunity id | 362196 |
| Closed opportunity pkgs 1 / Family id | 14 |
| Closed opportunity pkgs 1 / Dialect | XFDL2.2 |
| Closed opportunity pkgs 1 / Opportunity number | HT942526ALSRPTDA |
| Closed opportunity pkgs 1 / Opportunity title | DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award |
| Closed opportunity pkgs 1 / Cfda number | 12.420 |
| Closed opportunity pkgs 1 / Opening date | May 04, 2026 12:00:00 AM EDT |
| Closed opportunity pkgs 1 / Closing date | Sep 30, 2026 12:00:00 AM EDT |
| Closed opportunity pkgs 1 / Owning agency code | DOD-AMRAA |
| Closed opportunity pkgs 1 / Program title | Military Medical Research and Development |
| Closed opportunity pkgs 1 / Contact info | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Closed opportunity pkgs 1 / Grace period | 0 |
| Closed opportunity pkgs 1 / Electronic required | Y |
| Closed opportunity pkgs 1 / Expected application count | 23 |
| Closed opportunity pkgs 1 / Expected application size | 1000000 |
| Closed opportunity pkgs 1 / Open to applicant type | 1 |
| Closed opportunity pkgs 1 / Is multi project | N |
| Closed opportunity pkgs 1 / Extension | |
| Closed opportunity pkgs 1 / Mimetype | application/pdf |
| Closed opportunity pkgs 1 / Last update | May 04, 2026 09:48:06 AM EDT |
| Closed opportunity pkgs 1 / Workspace compatible flag | Y |
| Closed opportunity pkgs 1 / Package id | PKG00292625 |
| Closed opportunity pkgs 1 / Opening date str | 2026-05-04-00-00-00 |
| Closed opportunity pkgs 1 / Closing date str | 2026-09-30-00-00-00 |
| Original due date | Sep 30, 2026 12:00:00 AM EDT |
| Original due date desc | Not specified |
| Synopsis modified fields | Not specified |
| Forecast modified fields | Not specified |
| Error messages | Not specified |
| Syn post date in past | Yes |
| Doc type | synopsis |
| Forecast hist count | 0 |
| Synopsis hist count | 0 |
| Assist compatible | No |
| Assist url | Not specified |
| Related opps | Not specified |
| Ost | CLOSED |
Related Documents
Packages
| Agency Contact Information: | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00292625 | May 04, 2026 12:00:00 AM EDT | Sep 30, 2026 12:00:00 AM EDT | View |
